Tegaserod

FDA label

Read the full label on DailyMed ↗

Renal Contraindicated if severe (eGFR <15) or ESRD; no adjustment for mild-moderate (eGFR ≥30)

Hepatic Contraindicated if moderate-severe (Child-Pugh B or C); no adjustment for mild

Instructions

• Take orally ≥30 minutes before meals
• Discontinue if inadequate symptom control after 4–6 weeks

Available strengths

• tab 6 mg

Contraindications

• History of MI, stroke, TIA, or angina
• History of ischemic colitis or other intestinal ischemia
• Severe renal impairment (eGFR <15) or ESRD
• Moderate/severe hepatic impairment (Child-Pugh B or C)
• History of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions

Cautions

• Cardiovascular ischemic events including MACE — assess CV history/risk before use; discontinue if MI/stroke/TIA/angina
• Ischemic colitis — discontinue if rectal bleeding, bloody diarrhea, or new/worsening abdominal pain; do not reinitiate
• Volume depletion from diarrhea (hypovolemia, hypotension, syncope) — avoid in patients with diarrhea
• Suicidal ideation and behavior — monitor for worsening depression

Adverse reactions

• Headache, abdominal pain, nausea, diarrhea, flatulence, dyspepsia, dizziness

Pregnancy Available data have not identified a drug-associated risk of major birth defects or miscarriage

Lactation Breastfeeding not recommended during treatment (present in rat milk; tumorigenicity concern)